Algert Global LLC Has $334,000 Stake in Zoetis Inc. (NYSE:ZTS)

Algert Global LLC increased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 29.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,924 shares of the company’s stock after buying an additional 438 shares during the quarter. Algert Global LLC’s holdings in Zoetis were worth $334,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Webster Bank N. A. raised its position in Zoetis by 89.1% during the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after purchasing an additional 82 shares in the last quarter. Neo Ivy Capital Management bought a new stake in Zoetis during the fourth quarter valued at $40,000. LRI Investments LLC acquired a new stake in Zoetis during the first quarter worth approximately $43,000. Hazlett Burt & Watson Inc. boosted its holdings in shares of Zoetis by 60.7% during the 1st quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock worth $46,000 after buying an additional 102 shares in the last quarter. Finally, Central Valley Advisors LLC acquired a new stake in Zoetis in the second quarter worth $49,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

NYSE ZTS opened at $187.37 on Wednesday. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. The company has a market cap of $84.89 billion, a PE ratio of 36.03, a price-to-earnings-growth ratio of 2.91 and a beta of 0.89. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The firm’s 50-day simple moving average is $187.41 and its two-hundred day simple moving average is $175.64.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, topping the consensus estimate of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The company had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. During the same period last year, the firm earned $1.41 EPS. Zoetis’s revenue for the quarter was up 8.3% on a year-over-year basis. Research analysts predict that Zoetis Inc. will post 5.84 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on ZTS shares. BTIG Research boosted their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Argus upgraded Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Piper Sandler upped their price objective on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Finally, Stifel Nicolaus lifted their target price on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $220.38.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.